Podcasts about Targeted therapy

  • 232PODCASTS
  • 1,093EPISODES
  • 39mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jun 19, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Targeted therapy

Show all podcasts related to targeted therapy

Latest podcast episodes about Targeted therapy

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 19: Insights and Innovations in B Cell Disorders

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Jun 19, 2025 29:38


Lydia Scarfò is a Physician Scientist at the B-cell Neoplasia Unit and an Assistant Professor at Università Vita-Salute San Raffaele, Milan, Italy.   She is involved in both clinical and pre-clinical studies, including being a co-investigator in over 20 clinical trials in haematological malignancies, including chronic lymphocytic leukaemia.  Timestamps:  0:00 – Introduction  1:14 – Quickfire questions  7:31 – Haematology inspiration  9:08 – STIL loss  11:42 – Splenic marginal zone lymphoma  13:03 – Novel targeted therapies for chronic lymphocytic leukaemia  17:35 – Covalent BTK inhibitors   19:30 – Chemo-free approach for hairy cell leukaemia  22:20 – Recent advances, challenges, and opportunities  25:58 – Three wishes 

Born to Heal Podcast with Dr. Katie Deming
Immunotherapy vs Chemotherapy: What Cancer Patients Need to Know with Dr. Jason Konnor, Medical Oncologist at Memorial Sloan Kettering | EP 99

Born to Heal Podcast with Dr. Katie Deming

Play Episode Listen Later Jun 17, 2025 48:40 Transcription Available


When your doctor says you need “cancer treatment,” do you know what that actually means?Most people immediately think of chemotherapy. But if you or someone you love is facing a cancer diagnosis, understanding the full range of treatment options could be the difference between feeling overwhelmed and feeling empowered.Dr. Katie Deming sits down with Dr. Jason Konner, a medical oncologist at Memorial Sloan Kettering Cancer Center, to break down the three main types of systemic cancer treatment used today: chemotherapy, targeted therapies, and immunotherapies.Chapters:03:43 – Three Main Types of Cancer Treatment16:34 – Why First-Line Therapies Matter20:48 – Combining Holistic and Conventional Care31:23 – Essential Questions to Ask Your Oncologist43:42 – When and Why to Seek a Second OpinionDr. Konnor shares the insider perspective on second opinions, what those complex drug names really mean, and how to build the kind of relationship with your medical team that leads to better outcomes.You'll learn how some patients unknowingly sabotage their own care and what questions can instantly make you a more informed patient. Listen and learn how to walk into any oncologist's office with confidence, ask the right questions, and truly understand your options.Don't let medical jargon and complex choices keep you in the dark when clear thinking matters most.Reserve Your Spot for the June PSYCH-K® Online Workshop: https://www.katiedeming.com/psych-k-june-2025 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

PVRoundup Podcast
Advances in Treating HER2-Mutant Lung Cancer: Efficacy

PVRoundup Podcast

Play Episode Listen Later Jun 6, 2025 9:03


Stephen V. Liu, MD and Susan C. Scott, MD discuss advances in treating HER2-mutant lung cancer. Until recently, treatments for HER2-mutant lung cancer primarily involved chemotherapy, immunotherapy, and HER2-targeted therapies, with mixed results. Now, the treatment landscape of HER2-mutant lung cancer is changing.

CME Outfitters, LLC Podcasts
The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD

CME Outfitters, LLC Podcasts

Play Episode Listen Later Jun 6, 2025 82:04


PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 4, 2025 50:28


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 4, 2025 50:34


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 4, 2025 50:28


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 4, 2025 50:34


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 4, 2025 50:34


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Catherine Shu, MD, Gavitt Woodard, MD, FACS - Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 4, 2025 50:28


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKV865. CME/MOC/CC/AAPA credit will be available until June 13, 2026.Harnessing Precision With EGFR-Targeted Therapy in Resectable NSCLC: Evidence, Cases, and Considerations for Multidisciplinary Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

PeerVoice Clinical Pharmacology Audio
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Clinical Pharmacology Audio

Play Episode Listen Later May 27, 2025 20:12


Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Internal Medicine Audio
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Internal Medicine Audio

Play Episode Listen Later May 27, 2025 20:12


Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Internal Medicine Video
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Internal Medicine Video

Play Episode Listen Later May 27, 2025 20:12


Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Clinical Pharmacology Video
Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

PeerVoice Clinical Pharmacology Video

Play Episode Listen Later May 27, 2025 20:12


Maria Dall'Era, MD - When They Need Targeted Therapy: Selecting the Optimal Treatment Approach for Lupus Nephritis in an Evolving Treatment Landscape

Adis Journal Podcasts
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast Discussion

Adis Journal Podcasts

Play Episode Listen Later May 23, 2025 38:07


·         In this podcast, the authors discuss the current therapeutic landscape of NSCLC with actionable alterations and provide their perspectives on treatment algorithms, and how to optimally sequence therapies for patients with tumors harboring actionable alterations, using patient cases to illustrate key principles. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03195-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. 

Oncology Brothers
Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)

Oncology Brothers

Play Episode Listen Later May 8, 2025 15:05


In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: •⁠  ⁠Overview of the treatment landscape for biliary tract cancer •⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue •⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care •⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions •⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 16: A Journey Through Leukaemia Research

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later May 8, 2025 37:09


In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

PVRoundup Podcast
Could a new HER2-targeted therapy change outcomes in previously treated NSCLC?

PVRoundup Podcast

Play Episode Listen Later May 6, 2025 5:11


This episode features the Beamion LUNG-1 trial, where zongertinib showed a 71% response rate in previously treated HER2-mutant NSCLC patients. The EAGLE-1 trial found gepotidacin non-inferior to standard treatment for urogenital gonorrhoea, with a 92.6% success rate. The U.S. Department of Health and Human Services and NIH launched the Generation Gold Standard initiative, a universal vaccine platform targeting pandemic-prone viruses, with trials ongoing for H5N1 avian influenza and coronaviruses.

Oncology Brothers
Overview of Biliary Tract Cancer & Importance of Targeted Therapies

Oncology Brothers

Play Episode Listen Later Apr 24, 2025 18:23


Welcome to the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Ghassan Abou-Alfa, a medical oncologist specializing in the hepatobiliary space at Memorial Sloan Kettering. Together, they explored the current treatment landscape of biliary tract cancer, focusing on the advancements in HER2-driven therapies.   Key topics discussed included: • The evolution of treatment options for biliary tract cancer, including chemotherapy and immunotherapy. • The significance of genetic testing, including IDH1 mutations, FGFR alterations, and HER2 status. • The role of multidisciplinary collaboration in managing hepatobiliary cancers. • Insights into the latest clinical trials and emerging therapies for HER2-positive biliary tract cancer.   Join us as we delve into the complexities of biliary tract cancer and the promising developments in HER2-targeted treatments. Don't forget to check out our next episode, where we will take a deeper dive into the data surrounding HER2 therapies and discuss management strategies for common side effects.   YouTube: https://youtu.be/pGiU7JJGNOc   Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/   Subscribe to stay updated on the latest in oncology! #OncologyBrothers #BiliaryTractCancer #HER2 #CancerTreatment #MedicalOncology #CME #Podcast

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 15: Understanding B cell Metabolism in Lymphoma

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Apr 24, 2025 40:18


In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

CCO Oncology Podcast
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

CCO Oncology Podcast

Play Episode Listen Later Apr 24, 2025 18:34


In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland

Australian Prescriber Podcast
E186 - Calcitonin gene-related peptide–targeted therapies for migraine

Australian Prescriber Podcast

Play Episode Listen Later Apr 21, 2025 22:31


Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.

Authentic Biochemistry
Chimeric Antigen Receptor T Lymphocytes. I. Authentic Biochemistry Podcast..13APRIL25

Authentic Biochemistry

Play Episode Listen Later Apr 14, 2025 52:22


ReferencesSignal Transduction and Targeted Therapy 2019. volume 4, Article number: 7 JAMA. 2024 Dec 10;332(22):1924–1935. ACS Nano , 2025.January 27.Vol 19/Issue 5Guerra, DJ. 2025. Unpublished Lectures.Clapton &Whitlock. 1970."Why does Love have to be so Bad?" on LAYLA lp.https://open.spotify.com/track/6S5DtyJNXTgHEXIVUToAPP?si=e2c45a57168f4f6eAllman, D 1970 "Little Martha" on EAT A PEACH lp.https://open.spotify.com/track/2WPLFvAldG0GG6Ad3Xa0TO?si=8d5e8ed3fa934860Mozart, WA. 1791 "Clarinet Concerto in A Major. K.622https://open.spotify.com/album/5PerO11RxVNvixJPjW4UAl?si=2Jnw72E6QueNO6I9ff6Wzw

MoneyBall Medicine
Revolutionizing Cardiovascular Care with AI

MoneyBall Medicine

Play Episode Listen Later Apr 1, 2025 56:28


00:00 Introduction and Overview of Caristo Diagnostics09:08 The Technology Behind Carry Heart18:00 Clinical Implications and Risk Assessment27:27 Actionable Steps for Patients30:34 Optimizing Cardiovascular Drug Dosing32:31 AI in Cardiovascular Medicine33:50 Leveraging Historical Data for Risk Prediction36:25 AI's Role in Molecular Pathway Analysis39:03 GLP-1 and Cardiovascular Outcomes41:56 Targeted Therapies in Cardiovascular Treatment42:45 Building Trust in New Technologies49:16 Regulatory Approvals and Future Prospects54:15 Expanding Applications Beyond Cardiology57:16 Looking Ahead: The Future of Caristo Diagnostics 

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Apr 1, 2025 64:32


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZK865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 26, 2026.ALK+ mNSCLC Care Compass: Taking Your Best Shot First—Selecting and Sequencing Targeted Therapy and Teaming Up to Achieve Long-Term Success In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

PVRoundup Podcast
HER2 Alterations in Lung Cancer

PVRoundup Podcast

Play Episode Listen Later Mar 31, 2025 8:52


Drs. Sabari and Yu discuss the molecular landscape of HER2-mutant lung cancer, including its genomic characteristics, common co-mutations, and differences between HER2 mutations and HER2 amplification. This discussion also explores the prevalence and clinical patterns of HER2 mutations, their oncogenic mechanisms, their impact on tumor behavior and metastases, and potential environmental or genetic contributors to their development.

ReachMD CME
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC

ReachMD CME

Play Episode Listen Later Mar 31, 2025


CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

JAMA Network
JAMA Surgery : Molecular Testing and Targeted Therapies in Hepatobiliary Cancers

JAMA Network

Play Episode Listen Later Mar 19, 2025 12:47


Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers

JAMA Surgery Author Interviews: Covering research, science, & clinical practice in surgery to assist surgeons in optimizing p

Interview with Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA, author of Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review. Hosted by Amalia Cochran, MD. Related Content: Molecular Testing and Targeted Therapies in Hepatobiliary Cancers

Cancer Buzz
Supporting Skin Health in Patients with Breast Cancer

Cancer Buzz

Play Episode Listen Later Mar 11, 2025 12:33


Dermatologic toxicities associated with oncology treatment can significantly impact quality of life and treatment adherence for patients with breast cancer. The Association of Cancer Care Centers (ACCC) is committed to providing up-to-date guidance on managing these dermatologic side effects to enhance clinical outcomes. In this episode of CANCER BUZZ, Allison Gordon, MD, a supportive oncodermatologist at Memorial Sloan Kettering Cancer Center, discusses the dermatologic toxicities associated with breast cancer treatment. Dr Gordon explores preventive measures that oncologists can implement early in the treatment course and offers alternative resources for oncology clinicians when an oncodermatologist referral is not feasible. Additionally, she highlights capivasertib, a recently approved antineoplastic drug, and reviews its associated cutaneous adverse events, along with supportive care and management strategies. Thank you to AstraZeneca for their support of this program.   Allison Gordon, MD Dermatologist Memorial Sloan Kettering Cancer Center New York, NY   “Because many of these medications can cause dry skin, which can be debilitating for patients... [we recommend] using a thick ointment or cream moisturizer on their damp skin after they shower... it doesn't have to be anything expensive... I always recommend that to all patients regardless of what treatment they're on.”– Allison Gordon, MD    Additional Reading/Sources  ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies education program (https://www.accc-cancer.org/home/learn/comprehensive-cancer-care-services/dermatologic-toxicities?)   Targeted Therapy Side Effects – American Cancer Society  (https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/side-effects.html)   Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569770/)   Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy (https://ascopubs.org/doi/10.1200/EDBK_289911)   Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatolgy Study Group (https://mascc.org/resources/mascc-guidelines/)   Guidelines for the Prevention and Treatment of Radiation-Induced Skin Reactions (https://mascc.org/resources/mascc-guidelines/)   Guidelines for Prevention and Management of Dermatological Toxicities Related to Anticancer Agents (https://pubmed.ncbi.nlm.nih.gov/33248228/)

Oncotarget
A Rare Genetic Shift That Helped Lung Cancer Evade Treatment

Oncotarget

Play Episode Listen Later Mar 11, 2025 6:06


What if a cancer treatment worked—until it suddenly didn't? A new case report, “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report,” published in Oncotarget, reveals how a non-small cell lung cancer (NSCLC) patient developed drug resistance through a rare genetic alteration, allowing the cancer to evade therapy. This unexpected finding highlights the importance of advanced genetic testing and personalized cancer treatments. Non-Small Cell Lung Cancer, Targeted Therapy and Drug Resistance Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for nearly 85% of all cases. Some patients with NSCLC have genetic mutations, such as ROS1 gene fusions, that drive tumor growth. These patients often respond well to targeted therapies like lorlatinib, a ROS1 inhibitor that blocks cancer growth. However, cancer is constantly evolving. Over time, it can develop resistance to targeted therapies, leading to treatment failure. Understanding these resistance mechanisms is crucial for precision oncology, the approach of tailoring cancer treatment based on a patient's unique genetic profile. Full. blog - https://www.oncotarget.org/2025/03/12/a-rare-genetic-shift-that-helped-lung-cancer-evade-treatment/ DOI - https://doi.org/10.18632/oncotarget.28682 Correspondence to - Wade T. Iams - wade.t.iams@vumc.org Video short - https://www.youtube.com/watch?v=HE_qSkcRZho About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The EMJ Podcast: Insights For Healthcare Professionals
Onc Now: Episode 12: The Future of Breast Cancer Immunotherapy

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Mar 5, 2025 29:18


In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Heather McArthur, Associate Professor in the Department of Medicine at University of Texas, UT Southwestern Medical Center, USA. They discuss recent advancements in breast cancer immunotherapy and the future of personalised care.  Timestamps:    00:00 - Introduction  01:20 - Transformative breakthroughs in immunotherapy  03:51 - Communicating new research to the public  05:48 - Racial disparities in cancer screenings  07:22 - Unmet needs in treating triple-negative breast cancer  11:48 - Genomic profiling and molecular pathways   13:30 - Barriers to personalised treatment plans  15:09 - Designing and conducting large-scale, international trials  19:16 - Optoacoustic imaging in cancer  22:52 - The ‘first' cell and the heterogeneity of breast tumours  25:21 – Heather's three wishes for healthcare 

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Joshua Sabari, MD - Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 3, 2025 21:41


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 3, 2025 21:41


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Joshua Sabari, MD - Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 3, 2025 21:41


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Joshua Sabari, MD - Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 3, 2025 21:41


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/KRC865. CME credit will be available until February 26, 2026.Modern Practice Principles in Lung Cancer—First Find the Targets, Then Treat With Precision: A Concise Guide for Biomarker Testing and EGFR-Targeted Therapy in NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Both are Johnson & Johnson companies.Disclosure information is available at the beginning of the video presentation.

Lung Cancer Considered
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate

Lung Cancer Considered

Play Episode Listen Later Feb 28, 2025 25:28


Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC

The EMJ Podcast: Insights For Healthcare Professionals
Hema Now: Episode 11: Decoding Leukaemia's Epigenetic Drivers

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Feb 26, 2025 24:58


This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

Lung Cancer Considered
Live from TTLC25: Targeted Therapy in SCLC

Lung Cancer Considered

Play Episode Listen Later Feb 20, 2025 29:22


In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation. Guest: Triparna Sen, MD Associate Professor Director, Lung Cancer PDX Program, Icahn School of Medicine at Mount Sinai Guest: Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

JCO Precision Oncology Conversations
JCO PO Article Insights: Therapy of Infantile Midline Low-Grade Gliomas

JCO Precision Oncology Conversations

Play Episode Listen Later Feb 20, 2025 5:32


In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” by Dr. Ludmila Papusha et al. published on July 08, 2024. TRANSCRIPT  Jiasen He: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Jiasen He, a JCO Journal's Editorial Fellow. Today, I will provide a summary on “Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies.” This is an observational study by Dr. Ludmila Papusha and colleagues that investigated the use of target therapies in early childhood with midline low grade glioma. Low grade glioma located in the hypothalamic chiasmatic region, thalamus and the brain stem are classified as midline low grade gliomas. Due to their unique locations, complete surgical resection is usually not able to be achieved. In young children with low grade glioma, radiation therapy is generally not favored. Traditionally, chemotherapy regimens such as carboplatin and vincristine have been used. However, as Dr. Papusha noted, this population often exhibits poor response to chemotherapy. With a growing understanding of the RAS-RAF-MEK pathways in low grade glioma, targeted therapy has emerged as a promising treatment option for this group. However, limited data is available regarding the mutation status of midline low grade glioma in early childhood and real world evidence on their response to targeted therapy remains scarce. Dr. Papusha's research aimed to address this critical gap by evaluating the effectiveness of targeted therapy in midline gliomas of early childhood. In this observational study, 40 patients under the age of three with midline low grade glioma were enrolled. Somatic genetic aberrations associated with activation of RAS-RAF signaling pathway were identified in 95% of the cohort with BRAF fusion being the most common aberration followed by the BRAF V600E mutation. These findings confirm the presence of targetable mutations in this specific population and provide a foundation for the use of targeted therapy. Diencephalic syndrome is a rare neurologic disorder typically affecting infants and young children with tumors located in the diencephalon. In this cohort, 43% of the optic pathway and hypothalamic gliomas manifested diencephalic syndrome. Among 30 patients who received first line chemotherapy, primary carboplatin and vincristine, the two-year and five-year progression-free survival rate were only 24% and 6.4% respectively, indicating that most patients experience disease progression with chemotherapy. Targeted therapy was administered to 27 patients of whom 22 experienced disease progression during or after chemotherapy. A total of 26 patients were available for evaluation. Dr. Papusha reported that all patients benefited from targeted therapy with 12 achieving a partial response, 2 showing a minor response and 12 maintaining stable disease. The median duration of targeted therapy was 16 months. These findings demonstrate the efficacy of targeted therapy in this population. Regarding toxicity from targeted therapy in this population, the most common adverse event was grade 1 to 2 skin toxicity observed in 52% of patients. Severe toxicity occurred in 36% of patients treated with trametinib including grade 3 skin toxicity, mucositis and hematuria. Additionally, grade 3 gastrointestinal toxicity was reported. Interestingly, all three patients who experienced grade 3 gastrointestinal toxicity had diencephalic syndrome at the time of targeted therapy initiation. The author also noted cases of disease progression during treatment breaks. However, tumor response was restored in all affected patients upon resumption of targeted therapy. The two-year progression-free survival rate was 59%. In conclusion, Dr. Papusha states the unique characteristics of infantile midline low grade glioma, including the high prevalence of diencephalic syndrome and resistance to chemotherapy. The study contributes valuable information on the targetable mutation profile in this population and provides further evidence supporting the use of targeted therapy while emphasizing the need for low monitoring of severe adverse events. As the author notes, important questions remain regarding the long term side effects of kinase inhibitors in infants and children as well as optimal duration of therapy. Thank you for listening to JCO Precision Oncology Article Insights and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Research To Practice | Oncology Videos
HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies

Research To Practice | Oncology Videos

Play Episode Listen Later Feb 14, 2025 121:57


Featuring slide presentations and related discussion from Dr Joyce O'Shaughnessy, Dr Mark Pegram and Prof Peter Schmid, including the following topics: Strategies to Identify Patients with HER2-Low and HER2-Ultralow Breast Cancer (0:00) Case: A woman in her mid 50s initially presenting with ER-positive, HER2 IHC 1+ locally advanced breast cancer who experiences progression to HER2 0 metastatic disease (20:53) Case: A woman in her early 60s with ER-positive, HER2 IHC 1+ metastatic breast cancer (mBC) who experiences disease progression 8 months after starting first-line CDK4/6 and aromatase inhibitor (29:14) Expanding the Spectrum of Targeted Therapy (38:52) Case: A woman in her early 60s with HR-positive, HER2 IHC 1+ mBC who receives fifth-line T-DXd resulting in stable disease (1:04:13) Case: A woman in her early 50s with progressive HR-positive, HER2 IHC 0 mBC and an ESR1 mutation who has ultralow HER2 expression on rebiopsy of new liver lesions (1:12:35) Identification and Management of Adverse Events with T-DXd (1:20:27) Case: A woman in her late 40s with HR-positive, HER2 IHC 2+ mBC who experienced persistent low-grade nausea with T-DXd that resolved with olanzapine (1:34:02) Case: A woman in her early 60s with ER-positive, HER2 2+ mBC who received T-DXd resulting in fatigue and asymptomatic interstitial lung disease (1:48:58) CME information and select publications  

The Future of Everything presented by Stanford Engineering

Guest Kristy Red-Horse is a biologist who specializes in coronary artery development and disease. She says the latest advances in treatment of blockages could do away with invasive bypass surgeries in favor of growing new arteries using molecules like CXCL12, known to promote artery regrowth in mice. Red-Horse explains how leaps forward in medical imaging, expanding atlases of gene expressions, and new drug delivery mechanisms could someday lead to trials in humans. But, before that day can arrive, much work remains, as Red-Horse tells host Russ Altman in this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Kristy Red-HorseKristy's Lab: Red-Horse LabConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces Kristy Red-Horse, a professor of biology at Stanford University.(00:03:46) Replacing Open-Heart SurgeryWhy bypass surgery is invasive, risky, and requires long recovery.(00:05:09) Challenges in Artery GrowthThe difficulty of targeting artery growth with medical interventions.(00:07:32) The Role of Collateral ArteriesDefinition and function of collateral arteries as natural bypass.(00:09:37) Triggers for Natural Bypass FormationGenetic factors that may influence the growth of these bypass arteries.(00:10:49) Unique Properties of Coronary ArteriesChallenges of ensuring artificial growth replicates natural artery function.(00:13:04) The Discovery of CXCL12A key molecule that stimulates collateral artery formation.(00:16:16) Precise Artery Growth ControlThe results of targeted CXCL12 injections into mice hearts.(00:17:32) CXCL12's Overlooked RoleThe molecule's role in the immune system and stem cells.(00:20:27) Guinea Pigs and Heart Attack ResistanceHow guinea pigs naturally develop collaterals.(00:23:19) Preventing Heart DiseaseUsing artery growth treatments to target early-stage coronary disease.(00:25:25) Breakthroughs in Imaging TechnologyNew technology that enables identification of collateral growth pathways.(00:27:07) How Collateral Arteries FormThe two mechanisms in which new arteries form.(00:28:48) The Future of Medical Artery GrowthThe possibility of eliminating bypass surgery with targeted artery growth. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Geoffrey Ku, MD - Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Feb 14, 2025 90:46


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJJ865. CME/MOC/CE/AAPA/IPCE credit will be available until February 24, 2026.Fortifying the Framework for HER2+ GI Cancers: Precision Treatment Planning With Molecularly Targeted Therapies in GC/GEJC, CRC, and BTC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

Take Back Your Health
42. From Diagnosis to Thriving: How Taylor Dukes Chose Integrative Medicine to Heal Brain Cancer

Take Back Your Health

Play Episode Listen Later Feb 10, 2025 48:58


A free way to support your cancer treatment? Shifting your mindset and finding the positives in life. This week, I'm joined by Taylor Dukes, a family nurse practitioner, mother of two, and former colleague. We sat down to discuss her cancer journey—from finding out she had a brain tumor to entering remission—what she's learned in the years since her initial diagnosis, and how reframing her mindset helped her thrive. In this episode, you'll discover: Integrative Approaches to Cancer Treatment: When doctors found a brain tumor in Dukes' right frontal lobe, the mother of two didn't jump straight into surgery. Instead, she implemented a lot of integrative therapies such as coffee enemas, hyperbaric oxygen chamber therapy, wearing a red light helmet, and more. "In the five months between when I got diagnosed and when I actually had surgery, we were able to shrink the brain tumor in half," says Duke."  The Power of Positive Thinking: Dukes, who currently has "no evidence of disease," believes that as long as you're breathing, there is always hope and there are always options. "No diagnosis, no test, no statistic has the ability to figure out the number of your days," says Dukes, who credits prayer and meditation for her mindset. "Your mind is powerful and what you believe is so, so powerful." Maintaining Your Health After Cancer: Two years after her diagnosis, Dukes is now in maintenance mode and focuses on getting her immune system back on track. She keeps up with regular fasting, eats a lower-carb diet, and alternates between red light therapy, ozone therapy, and sauna. “I'm starting specific therapies to target the co-infections and Lyme markers I have,” she says. 06:40 A Life-Changing Diagnosis 10:15 Integrative Approach to Healing 18:19 The Power of Faith and Family 20:26 Life After Surgery 24:41 Immune System Suppression and Cancer Growth 25:01 Prevention and Immune System Recovery 25:26 Targeted Therapies and Integrative Approaches 26:55 Conventional vs. Integrative Treatment Options 31:11 Support Systems and Personal Decisions 34:08 Navigating Parenthood During Cancer 37:55 Coping Mechanisms and Emotional Resilience Connect with Dr. Myers: Website: https://www.amymyersmd.com/ Newsletter: https://www.amymyersmd.com/ec/guide-to-leaky-gut Facebook: https://www.facebook.com/AmyMyersMD Instagram: https://www.instagram.com/amymyersmd/ Connect with Taylor Dukes: Website: https://taylordukeswellness.com/ Online store: https://shop.taylordukeswellness.com/collections/all-products Instagram: https://www.instagram.com/taylordukeswellness/ Facebook: https://www.facebook.com/taylordukeswellness/ Tik Tok: https://www.tiktok.com/@taylordukeswellness

Cancer Buzz
Supportive Oncodermatology: Managing Skin, Hair, and Nail Toxicities in Cancer Care

Cancer Buzz

Play Episode Listen Later Jan 21, 2025 9:52


Synopsis: Adverse reactions involving the skin, nails, and hair are common among patients undergoing treatment for cancer and are often underreported and overlooked. These reactions directly impact patient quality of life and may be the reason for interruptions in lifesaving antineoplastic treatment. To address these toxicities, the Association of Cancer Care Centers (ACCC) is leading an initiative that aims to educate providers and other cancer care team members about the optimal management of dermatologic side effects.     In this episode, CANCER BUZZ speaks with Julie Ryan Wolf, PhD, MPH and C.J.G. (Corina) van den Hurk, PhD, the chair and vice chair of the Oncodermatology Study Group at the Multinational Association of Supportive Care in Cancer (MASCC) about common oncodermatological toxicities including radiation dermatitis, hair loss, and nail changes unique to EGFR-inhibitors. Also discussed are strategies to increase provider collaboration to intervene at an early stage to improve quality of life for patients receiving cancer treatment.   “If we have symptom monitoring on a regular basis throughout the course of treatment, we'll be able to intervene sooner… helping improve [patient] quality of life” – Julie Ryan Wolf, PhD, MPH   “In effect, almost each patient has a dermatologic side effect at the end of the treatment, or has experienced that during the treatment, and they are all very interfering.” – CJG (Corina) van den Hurk, PhD                     Julie Ryan Wolf, PhD, MPH   Chair, Oncodermatology Study Group  Multinational Association of Supportive Care in Cancer (MASCC)  Associate Professor, Department of Dermatology, Department of Radiation Oncology   University of Rochester Medical Center   Rochester, NY      CJG (Corina) van den Hurk, PhD   Vice Chair, Oncodermatology Study Group  Multinational Association of Supportive Care in Cancer (MASCC)  Senior Researcher, Santeon Hospitals   Netherlands         Thank you to Johnson & Johnson for their support of this program.     Additional Reading/Sources     Multinational Association of Supportive Care in Cancer (MASCC) Home  Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group   MASCC Study Group Evidence-Based Clinical Practice Guidelines   ACCC Supportive Care Strategies for Dermatologic Toxicities Related to Cancer Therapies  Oncology Issues – Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies  Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy  Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors  Supportive oncodermatology-a narrative review of its utility and the way forward =